FDA Draft Guidance for Medical Product Communications
By Alan Bergstrom -
Published 13 September 2017
This article focuses on the US Food and Drug Administration's (FDA's) draft guidance as it impacts prescription drug promotion and offers examples regarding information considered consistent with labeling. It emphasizes the need for regulatory professionals to better understand and adhere to FDA's evidentiary standards by utilizing examples of the Office of Prescription Drug Promotion (OPDP), formerly Division of Drug Marketing and Communications, enforcement actions that should be considered when interpreting what is "consistent with labeling."
Categories: Features, FDA, Communication, Labeling
Tags: Communication, Labeling